# Latticon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/latticon

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Latest round: Series A (Sep 20, 2026)
- Investors on record: 5

## About

Based in Jiangsu, China and founded in 2020 by Yuehua Li, Latticon (Suzhou) Biopharmaceuticals Co., Ltd., trading as Latticon, utilizes technologies such as antibody fusion proteins, bispecific antibodies, and complementary bispecific ADCs to develop innovative drugs to address unmet clinical needs.
In September 2026, Latticon closed Series A and Series A+ funding.
The company focuses on malignant tumors and autoimmune diseases, utilizing cutting-edge antibody technologies such as antibody fusion proteins, bispecific antibodies, and complementary bispecific ADCs to develop innovative drugs with enhanced safety, better clinical efficacy, and global intellectual property.
The company generates revenue through drug manufacturing, medical research and experimental development, engineering and technology research and experimental development, technology transfer, and technology promotion.
The Series A and Series A+ funding will primarily be used to accelerate the clinical translation of the company's myeloid cell engager technology.

## Funding rounds

- Series A, Sep 20, 2026 — Cathay Capital, China International Capital Corporation
- Series A, Sep 20, 2026 — China International Capital Corporation, Huagai Capital, Shenzhen Capital Real Estate Fund
- Series A, Aug 12, 2025 — HighLight Capital

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A
- Cathay Capital — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A